Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc T.VPH

Alternate Symbol(s):  T.VPH.DB | VPHIF

Healthcare
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


TSX:VPH - Post by User

Valeo Pharma Inc > Q3 highlights
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(51)
•••
Comment by kooter33on Oct 07, 2020 4:52pm
134 Views
Post# 31683986

RE:RE:Q3 highlights

RE:RE:Q3 highlightsagreed! If they miss, it will get ugly.  He seems to be pretty confident that they will be a profitable EBITDA company.  I will take him at his word.  The short count is down significantly as of Oct 1st.  I suspect we will see that fall even further on the Oct 16th update from Shortdata.ca.

OCT 1 2020
69
4.805
116,000
4.375
144,918
4.504
SEP 16 2020
317
23.021
839,400
27.971
962,858
27.574

OCT 1 2020
69
4.805
116,000
4.375
144,918
4.504
SEP 16 2020
317
23.021
839,400
27.971
962,858
27.574

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities